2006: milestone & pipeline

Discovery

1 new lead generation: MABA
2 new lead compounds: γ secretase 5074; PDE4 inhibitor 5480
1 new clinical candidate: M3 antagonist 5407
Synthetic Surfactant: Target Product Profi le defi nition
Next® DPI

Clinical Development

Phase II studies on carmoterol single agent and in association with budesonide

Registrations & launches

Foster® in Germany: MRP successfully completed in 15 EU countries in early 2007
BDP Modulite® in the United Kingdom
Bramitob®: MRP successfully completed in 12 EU countries


  Copyright© 2007 Chiesi Farmaceutici SpA. All rights reserved. Last update: 30/06/2007 (final results 2006).
All mentions and descriptions of products solely provide information on Chiesi’s activities and are not intended to indicate the advisability of administering any product in any particular instance.